Quoin Pharmaceuticals, Ltd. (QNRX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Ashburn, VA, United States. The current CEO is Michael Myers.
QNRX has IPO date of 2016-08-01, 3 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $3.71M.
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
